Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TRUST-III
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- NCT06564324 ↗
- Recruiting
- Nuvation Bio Inc.
- Focused
We haven't built an HCP commentary report on TRUST-III (taletrectinib and crizotinib in Non Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TRUST-III so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Taletrectinib; Crizotinib
- Arms
- Taletrectinib · Experimental
- Crizotinib · Active comparator
- Enrollment
- 194 (estimated)
- Primary outcomes
- PFS (Assessed by BIRC)
- Sponsor
- Nuvation Bio Inc.
- Start
- Nov 27, 2024
- Primary completion
- Jan 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06564324 · updated Apr 13, 2026